Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Discontinues PPAR Candidate Galida

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety issues have plagued development of the diabetes treatment class.

You may also be interested in...



AstraZeneca Turns Gaze On Global Impact Of Diabetes Crisis

HONG KONG - If viral diseases were the scourge of the nineteenth and twentieth centuries, diseases born of more effective healthcare and wealth might represent the next threat. Prominent among them is diabetes, which causes about 5 percent of deaths around the world every year

Bristol Aims To Be First To Market With Novel Diabetes Drug Class

Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.

Bristol Aims To Be First To Market With Novel Diabetes Drug Class

Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.

Related Content

Topics

UsernamePublicRestriction

Register

PS064272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel